The regrouping of Luminal B (HER2 negative), a better discriminator of outcome and recurrence score
Abstract Background Breast cancer (BC) remains the leading cause of cancer‐related deaths worldwide. High recurrence risk Luminal BC receives adjuvant chemotherapy in addition to standard hormone therapy. Considering the heterogeneity of Luminal B BC, a more accurate classification model is urgently...
Saved in:
| Main Authors: | Zheng‐Jun Yang, Yu‐Xiao Liu, Yue Huang, Zu‐Jin Chen, Hao‐Zhi Zhang, Yue Yu, Xin Wang, Xu‐Chen Cao |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-02-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.5089 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
ADJUVANT CHEMOTHERAPY OF PRIMARY OPERABLE LUMINAL B BREAST CANCER WITHOUT OVEREXPRESSION OF HER2/NEU IN POSTMENOPAUSAL WOMEN: YES OR NO?
by: Yu. S. Shatova, et al.
Published: (2017-12-01) -
Luminal breast cancer identity is determined by loss of glucocorticoid receptor activity
by: Stefan Prekovic, et al.
Published: (2023-10-01) -
MORPHOLOGICAL STUDY OF LUMINAL BREAST CANCER
by: M. V. Zavyalova, et al.
Published: (2016-02-01) -
Prognostic Importance of PTEN and P53 in Aggressive Luminal A Subtype Breast Cancers
by: Öykü Dila Gemci, et al.
Published: (2025-07-01) -
Immunological and molecular genetic characteristics of luminal B breast cancer: a literature review
by: D. A. Ryabchikov, et al.
Published: (2017-02-01)